For secondary melanomas, the varying time to presentation may be associated with the immune system’s control of tumor growth: a better prognosis may be connected with the presence of tumor-specific lymphocytes, such as tyrosinase-related protein (TRP)-1, TRP-2, melanoma antigen recognized by T cells (Melan-A/MART-1), glycoprotein (gp) 100, and tyrosinase (3). This evidence concerns the gene TYR and melanoma.